Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102-IO103 + Pembrolizumab in Advanced Melanoma
NCT05155254Phase 3Active, not recruiting
- Sponsor
- IO Biotech
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 16
01
Overview
A Phase 3 trial of PD-L1/IDO peptide vaccine in melanoma, sponsored by IO Biotech. Started May 2022; status: active, not recruiting.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05155254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155254.